Replay available

Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) Q4 2025 earnings conference call, held 2026-02-19. Replay captured from the company's public earnings webcast.

Thu, February 19, 2026 at 8:00 AMendedReplay
Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dan Ferry

Investor Relations

Marcio Souza

President and Chief Executive Officer

Tim Kelly

Chief Financial Officer

Yasmine Rahimi

Piper Sandler Analyst

Athena Chin

TD Cowen Analyst

Guggenheim Analyst

Analyst

Jun Li

Truist Securities Analyst

Andrew Say

Jefferies Analyst

Douglas Sal

H.C. Wainwright Analyst

Amy Fadia

Needham & Company Analyst

Brian Scorney

Robert W. Baird Analyst

Jay Olson

Oppenheimer Analyst

Unnamed BTIG Analyst

Analyst

Justin Walsh

JonesTrading Analyst

David Huang

Deutsche Bank Analyst

Ben Burnett

Wells Fargo Analyst

Replay transcript excerpt

and thank you for standing by. Welcome to the Praxis Precision Medicine's fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Dan Ferry, Investor Relations. Please go ahead. Good morning, and welcome to the Praxis Precision Medicine's fourth quarter and full year 2025 Financial Results and Business Update conference call. This call is being webcast live and can be accessed on the Investor section of Praxis' website at www.praxismedicines.com. Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent Praxis views as of today, they should not be relied upon as representing the company's views in the future. Praxis may update these statements in the future, but is not taking an obligation to do so. Please refer to Praxis' most recent filings of the Securities and Exchange Commission for discussion of certain risks and uncertainties associated with the company's business. Joining us on today's call are Marcio Souza, President and Chief Executive Officer of Praxis, and Tim Kelly, our Chief Financial Officer. After upda...

More from Praxis Precision Medicines, Inc.